You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Chronic Phase-CML (CP-CML)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Among CP-CML Participants Initiating Dasatinib inReal Life

Completed
  • Chronic Myeloid Leukemia
  • Non-Interventional
  • Paris, France
    Local Institution
Jun 17, 2022

Flumatinib, Chronic Myeloid Leukemia, Chronic Phase, Imatinib Trial in Shenzhen (Flumatinib)

Recruiting
  • Flumatinib
  • +2 more
  • Shenzhen, Guangdong, China
    The Second People's Hospital of Shenzhen
Mar 15, 2022

CML, Chronic Phase Trial in Harbin (Flumatinib, Imatinib)

Not yet recruiting
  • CML, Chronic Phase
  • Harbin, Heilongjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
May 5, 2022

Chronic Phase Chronic Myelogenous Leukemia Trial in Detroit, Milwaukee (Asciminib, Imatinib)

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • Detroit, Michigan
  • +1 more
May 3, 2022

Chronic Myeloid Leukemia in Chronic Phase Trial in Shenzhen (Flumatinib, Dasatinib)

Recruiting
  • Chronic Myeloid Leukemia in Chronic Phase
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022

Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors Trial in Shenzhen (olverembatinib)

Recruiting
  • Olverembatinib
  • +2 more
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Trial (Asciminib, Nilotinib)

Not yet recruiting
  • Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
  • (no location specified)
Jul 11, 2022

Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission Trial (Asciminib, Imatinib)

Not yet recruiting
  • Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
  • (no location specified)
Jun 7, 2022

Leukemia, Chronic Myelogenous Trial in China (asciminib, best available treatment)

Recruiting
  • Leukemia, Chronic Myelogenous
  • Chongqing City, Chongqing, China
  • +23 more
Jan 18, 2023

Chronic Myeloid Leukemia, Chronic Phase, Nilotinib Trial in Shenzhen (Nilotinib)

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • Nilotinib
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Mar 15, 2022

Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid

Recruiting
  • CML-CP; Mutation;Suboptimal Response or Failure in TKI
  • Wuhan, Hubei, China
    Weiming Li
May 31, 2021

CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic Trial in Worldwide (Asciminib add-on, Imatinib, Nilotinib)

Recruiting
  • CML
  • +3 more
  • Asciminib add-on
  • +3 more
  • Augusta, Georgia
  • +46 more
Jan 23, 2023

Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory Trial in Worldwide (Radotinib HCl)

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • +3 more
  • Radotinib HCl
  • Uijeongbu-si, Gyeonggi-do, Korea, Republic of
  • +17 more
Jan 3, 2022

CML, Philadelphia Chromosome Positive (Ph+), Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib

Terminated
Has Results
  • CML
  • +2 more
  • Las Vegas, Nevada
  • +2 more
Apr 28, 2021

Treatment Free Remission (TFR) in CML Patients (CML-CP)Study

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Treatment-free Remission
  • TFR(Treatment-Free Remission)
  • (no location specified)
Jun 27, 2022

3rd Line Therapy or More to Treat Adult CML- CP in Real World

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Asciminib
  • (no location specified)
Oct 16, 2023

Chronic Myelogenous Leukemia - Chronic Phase Trial in China (Dasatinib Tablets)

Completed
  • Chronic Myelogenous Leukemia - Chronic Phase
  • Dasatinib Tablets
  • Shenzhen, Guangdong, China
  • +3 more
Jun 11, 2021

Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

According to Molecular Identification at Diagnosis

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Next Generation Sequencing (DNA and RNA)
  • (no location specified)
Oct 28, 2022

Metabolic Alternation and Clinicohematological Characteristic in

Not yet recruiting
  • CML, Chronic Phase
  • Tyrosine kinase inhibitor
  • (no location specified)
Nov 6, 2023

CML, Imatinib Trial in Seoul (high-dose imatinib)

Completed
  • CML
  • Imatinib
  • high-dose imatinib
  • Seoul, Korea, Republic of
    Novartis Investigational Site
Mar 9, 2021

Needs of 3L+ CP-CML and With T315I-mutated CML Patients

Completed
  • Chronic Myeloid Leukemia
  • 3L Therapy
  • T315I
  • Lyon, France
    Novartis Investigative Site
Nov 9, 2022

Chronic Myelogenous Leukemia Trial in Worldwide (ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD)

Recruiting
  • Chronic Myelogenous Leukemia
  • ABL001 40mg BID
  • +2 more
  • Caba, Buenos Aires, Argentina
  • +53 more
Jan 27, 2023

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase

Recruiting
  • CML, Chronic Phase; TKI
  • Flumatinib Mesylate
  • Nilotinib Pill
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
Feb 1, 2021

CML, Chronic Phase, CML, Accelerated Phase Trial in Wuhan (HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion))

Recruiting
  • CML, Chronic Phase
  • CML, Accelerated Phase
  • HS-10382(Part 1: Dose escalation)
  • HS-10382(Part 2: Dose expansion)
  • Wuhan, Hubei, China
    Union Hospital affiliated to Tongji Medical College of Huazhong
Jan 12, 2023